Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protalix Biotherapeutics, Inc. on March 16, 2012. The filing serves as a Regulation FD disclosure regarding the scheduling of the Company's 2012 Annual Meeting of Shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance notification and does not contain financial performance data.
Material Changes
There are no material financial changes reported in this filing. The primary event is the Board of Directors' decision to set the record date for the upcoming Annual Meeting.
Guidance, Outlook, and Management Commentary
- Record Date: The Board has set May 5, 2012, as the record date for shareholders entitled to receive notice of and to vote at the 2012 Annual Meeting.
- Meeting Date and Location: The Annual Meeting is currently anticipated to be held on or around June 25, 2012, in Tel Aviv, Israel.
- Disclosure Status: The information contained in this report and the accompanying press release (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly referenced.
Investor Verification Checklist
- Verify the official record date of May 5, 2012, to ensure eligibility to vote at the Annual Meeting.
- Confirm the final date and location of the Annual Meeting, as the current date of June 25, 2012, is an anticipation.
- Review the full text of the press release (Exhibit 99.1) for any additional details on agenda items or proxy materials.